Finch Therapeutics Group (FNCH) Competitors

$8.15 +0.92 (+12.72%)

As of 05/1/2026

FNCH vs. ELUT, CUE, LITS, SCYX, and ZYBT

Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Elutia (ELUT), Cue Biopharma (CUE), Lite Strategy (LITS), SCYNEXIS (SCYX), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Finch Therapeutics Group compare to Elutia?

Elutia (NASDAQ:ELUT) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

: In the previous week, Elutia had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Elutia and 0 mentions for Finch Therapeutics Group. Elutia's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.
Company Overall Sentiment
Elutia Neutral
Finch Therapeutics Group Neutral
: Elutia has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
: Elutia presently has a consensus price target of $6.00, indicating a potential upside of 514.94%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Finch Therapeutics Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elutia
0 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.50
Finch Therapeutics Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Elutia has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Elutia $12.29M 3.40 $53.38M $0.82 1.19
Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A
: Elutia has a net margin of 282.63% compared to Finch Therapeutics Group's net margin of 0.00%. Elutia's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.
Company Net Margins Return on Equity Return on Assets
Elutia 282.63% N/A -49.57%
Finch Therapeutics Group N/A -69.14% -26.92%
: 74.0% of Elutia shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Overall Sentiment
Elutia	Neutral
Finch Therapeutics Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.40	$53.38M	$0.82	1.19
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Company	Net Margins	Return on Equity	Return on Assets
Elutia	282.63%	N/A	-49.57%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Summary

Elutia beats Finch Therapeutics Group on 11 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Cue Biopharma?

Finch Therapeutics Group (NASDAQ:FNCH) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

: Cue Biopharma has higher revenue and earnings than Finch Therapeutics Group. Cue Biopharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A
Cue Biopharma $27.47M 4.12 -$26.60M -$9.61 N/A
: 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 1.8% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Cue Biopharma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Finch Therapeutics Group has a net margin of 0.00% compared to Cue Biopharma's net margin of -96.85%. Finch Therapeutics Group's return on equity of -69.14% beat Cue Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Finch Therapeutics Group N/A -69.14% -26.92%
Cue Biopharma -96.85% -165.19% -77.77%
: In the previous week, Cue Biopharma had 8 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 8 mentions for Cue Biopharma and 0 mentions for Finch Therapeutics Group. Cue Biopharma's average media sentiment score of 0.29 beat Finch Therapeutics Group's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.
Company Overall Sentiment
Finch Therapeutics Group Neutral
Cue Biopharma Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Cue Biopharma	$27.47M	4.12	-$26.60M	-$9.61	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Cue Biopharma	-96.85%	-165.19%	-77.77%

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Cue Biopharma	Neutral

Summary

Cue Biopharma beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

: In the previous week, Lite Strategy's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.
Company Overall Sentiment
Lite Strategy Neutral
Finch Therapeutics Group Neutral
: Lite Strategy has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lite Strategy $65.30M 0.63 -$15.94M -$1.33 N/A
Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A
: Lite Strategy has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
: 52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Lite Strategy's return on equity of -68.86% beat Finch Therapeutics Group's return on equity.
Company Net Margins Return on Equity Return on Assets
Lite Strategy N/A -68.86% -67.48%
Finch Therapeutics Group N/A -69.14% -26.92%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Finch Therapeutics Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Lite Strategy	Neutral
Finch Therapeutics Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.63	-$15.94M	-$1.33	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-68.86%	-67.48%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Lite Strategy beats Finch Therapeutics Group on 7 of the 10 factors compared between the two stocks.

How does Finch Therapeutics Group compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

: SCYNEXIS has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: Finch Therapeutics Group has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -25.52% beat Finch Therapeutics Group's return on equity.
Company Net Margins Return on Equity Return on Assets
SCYNEXIS -41.79% -25.52% -19.33%
Finch Therapeutics Group N/A -69.14% -26.92%
: SCYNEXIS currently has a consensus price target of $3.00, indicating a potential upside of 218.17%. Given SCYNEXIS's stronger consensus rating and higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Finch Therapeutics Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Finch Therapeutics Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, SCYNEXIS had 8 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 8 mentions for SCYNEXIS and 0 mentions for Finch Therapeutics Group. SCYNEXIS's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.
Company Overall Sentiment
SCYNEXIS Neutral
Finch Therapeutics Group Neutral
: SCYNEXIS has higher revenue and earnings than Finch Therapeutics Group. SCYNEXIS is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SCYNEXIS $20.60M 2.04 -$8.61M -$0.17 N/A
Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A
: 54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-25.52%	-19.33%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
SCYNEXIS	Neutral
Finch Therapeutics Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.04	-$8.61M	-$0.17	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Summary

SCYNEXIS beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Zhengye Biotechnology?

Finch Therapeutics Group (NASDAQ:FNCH) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

: Zhengye Biotechnology has higher revenue and earnings than Finch Therapeutics Group.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A
Zhengye Biotechnology $16.64M 2.69 -$9.98M N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Zhengye Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the S&P 500.
: Zhengye Biotechnology's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.
Company Net Margins Return on Equity Return on Assets
Finch Therapeutics Group N/A -69.14% -26.92%
Zhengye Biotechnology N/A N/A N/A
: In the previous week, Zhengye Biotechnology's average media sentiment score of 0.69 beat Finch Therapeutics Group's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.
Company Overall Sentiment
Finch Therapeutics Group Neutral
Zhengye Biotechnology Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Zhengye Biotechnology	$16.64M	2.69	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Zhengye Biotechnology	N/A	N/A	N/A

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Zhengye Biotechnology	Positive

Summary

Zhengye Biotechnology beats Finch Therapeutics Group on 6 of the 9 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FNCH vs. The Competition

Export

Metric	Finch Therapeutics Group	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.09M	$329.01M	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	-0.92	N/A	29.25	27.07
Price / Sales	N/A	189.48	504.68	73.43
Price / Cash	N/A	22.44	43.30	53.90
Price / Book	0.57	4.73	9.67	6.69
Net Income	-$74.75M	-$132.96M	$3.55B	$332.64M
7 Day Performance	6.40%	6.97%	1.70%	2.01%
1 Month Performance	-14.21%	4.03%	5.62%	9.19%
1 Year Performance	-35.06%	37.44%	34.42%	39.59%

Finch Therapeutics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FNCH Finch Therapeutics Group	N/A	$8.15 +12.7%	N/A	-35.1%	$13.09M	N/A	N/A	190
ELUT Elutia	2.7766 of 5 stars	$1.02 +2.0%	$6.00 +488.2%	-48.6%	$42.78M	$12.29M	1.24	180	Gap Up
CUE Cue Biopharma	0.2357 of 5 stars	$14.74 +13.4%	N/A	-95.0%	$42.11M	$27.47M	N/A	60	Analyst Downgrade
LITS Lite Strategy	0.0678 of 5 stars	$1.15 flat	N/A	N/A	$41.82M	$65.30M	N/A	100	Positive News
SCYX SCYNEXIS	1.973 of 5 stars	$0.93 -0.5%	$3.00 +222.6%	-2.7%	$41.73M	$20.60M	N/A	60	Upcoming Earnings Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. ELUT, CUE, LITS, SCYX, and ZYBT

How does Finch Therapeutics Group compare to Elutia?

Summary

How does Finch Therapeutics Group compare to Cue Biopharma?

Summary

How does Finch Therapeutics Group compare to Lite Strategy?

Summary

How does Finch Therapeutics Group compare to SCYNEXIS?

Summary

How does Finch Therapeutics Group compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. ELUT, CUE, LITS, SCYX, and ZYBT

How does Finch Therapeutics Group compare to Elutia?

Summary

How does Finch Therapeutics Group compare to Cue Biopharma?

Summary

How does Finch Therapeutics Group compare to Lite Strategy?

Summary

How does Finch Therapeutics Group compare to SCYNEXIS?

Summary

How does Finch Therapeutics Group compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools